Telmisartan in the management of the cardiovascular disease continuum in the real world setting in India

Kumar, Amit and Chatterjee, Devashish and Saha, Debasish and Hansda, Samanta and Prasad T, Devi (2025) Telmisartan in the management of the cardiovascular disease continuum in the real world setting in India. World Journal of Advanced Research and Reviews, 27 (2). pp. 1886-1892. ISSN 2581-9615

Background: The cardiovascular disease continuum (CVDC) is a progressive sequence of events that may lead to advanced cardiovascular (CV) disease. This questionnaire-based study aims to provide insights into real-world effectiveness, safety and adherence of telmisartan in managing hypertension (HT) and associated CV conditions. Methods: This questionnaire-based study was conducted among Indian HCPs from between November 2024 to February 2025. A questionnaire comprising 16 questions explored preferences of health care professionals (HCPs) for use of telmisartan in last 10 patients with CVDC. Results: A total of 49 HCP were included in this study. The 65.31% of HCPs newly diagnosed < 5 patients with HT. Maximum HCPs (69.39%) noted diabetes mellitus has risk factor. In patients with long standing hypertension, both reduction of left ventricular hypertrophy and no progression to angina was noted by 79.59% of HCPs after treatment. A substantial majority of 69.39% of HCPs reported telmisartan controlled blood pressure (BP) for 24 hours. The ambulatory BP recording was done for 2 patients by 51.02% of HCPs. The 40.82% of HCPs reported single patient had undergone percutaneous coronary intervention. Well controlled BP was recorded by 51.02% HCPs. The 51.02% of HCPs indicated that 50% of diabetic patients reached their target BP in spite of the comorbid disease. Metoprolol was prescribed in combination therapy by 59.18% of HCPs. All the HCPs rated telmisartan efficacy, safety and adherence to treatment as excellent and good. Conclusion: This study revealed insights into telmisartan's efficacy, safety and adherence in management of HT.